Navigation Links
Abingdon Life Sciences, Inc. Announces Opening of Office in Carlsbad, Ca.
Date:7/21/2008

CARLSBAD, Calif., July 21 /PRNewswire/ -- Abingdon Life Sciences announces the formal opening of its offices in Carlsbad, California. The offices, located at 5963 La Place Court, Suite 107, are in the Carlsbad Airport Business Park adjacent to Palomar Airport. Abingdon Life Sciences, Inc. is a first-in-class Drug, Device, Diagnostic Development Management Organization (DDMO), focused on providing drug and device companies with superior services based on an integrated strategic development model. An integrated development model focuses on the Target Product Profile (TPP) concept, and allows a platform to be assessed by key areas of opportunity and risk from both scientific and business aspects.

Abingdon was founded on the principle that a proactive strategic approach to development will yield better outcomes. Abingdon's philosophy is to provide clients with a focused approach to product development by building synergistic partnerships that use significant expertise to achieve the best outcome. Global core-competencies include pre-clinical, regulatory strategy and submissions, clinical development, biostatistics, report writing and post-marketing obligations. Abingdon provides services to clients with products initially filed under IND, CTX, 505(b)(2), NDA, ANDA, PMA and 510k applications. Abingdon's senior executives provide personalized oversight and leadership of projects to ensure the best possible customer experience. Key alliances enable Abingdon to assist with cGMP services from formulation development for clinical trial supply through commercialization.

"Abingdon's approach is to reduce the noise in the development process and provide objective direction that outlines the risks and benefits of the potential development pathways. In the end, our goal is to assist our clients to streamline their development process and help make decisions that will achieve their goals. We believe this will ultimately reduce costs to our clients and speed the time to market," stated Aidan Nuttall, Ph.D., President and C.O.O., Abingdon Life Sciences, Inc.

About Abingdon Life Sciences, Inc.:

Abingdon Life Sciences, Inc. is a first-in-class Drug and Device Development Management Organization (DDMO) providing drug and device companies superior clinical and regulatory services based on an integrated strategic development model. Abingdon's senior executives provide personalized oversight and leadership of projects to ensure the best possible customer experience.


'/>"/>
SOURCE Abingdon Life Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use
2. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration
3. Dow AgroSciences, Martek Biosciences Form Alliance to Bring Omega-3 Fatty Acids to Food Industry
4. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
5. Pressure BioSciences, Inc. to Discuss First Quarter 2008 Financial Results and Provide Business Update
6. RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner
7. Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimers Disease
8. Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement
9. Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales
10. Pressure BioSciences, Inc. to Discuss 2007 Financial Results and Provide Business Update
11. DARA BioSciences, Inc. Announces Appointment of New Director to Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... set to take place on 7th and 8th June 2018 in San Francisco, CA. ... policy influencers as well as several distinguished CEOs, board directors and government officials from ...
(Date:10/11/2017)... ... October 11, 2017 , ... A ... pregnancy rates in frozen and fresh in vitro fertilization (IVF) transfer ... age to IVF success. , After comparing the results from the fresh and ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO ... Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative ... attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. ...
(Date:10/9/2017)... SAN DIEGO , Oct. 9, 2017 /PRNewswire/ ... a biological mechanism by which its ProCell stem ... of critical limb ischemia.  The Company, demonstrated that ... the amount of limbs saved as compared to ... of the molecule HGF resulted in reduction of ...
Breaking Biology Technology:
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
(Date:3/30/2017)... 30, 2017  On April 6-7, 2017, Sequencing.com will ... hackathon at Microsoft,s headquarters in ... focus on developing health and wellness apps that provide ... the Genome is the first hackathon for personal ... largest companies in the genomics, tech and health industries ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
Breaking Biology News(10 mins):